3 ms·
Why don't we spend $10M to bolster the review team and clear the queue instead of creating $150M worth of perverted incentives that the companies will inevitabl
by revelation 12y ago
Why don't we spend $10M to bolster the review team and clear the queue instead of creating $150M worth of perverted incentives that the companies will inevitably recoup from the health care system? Medicaid alone will probably pay more than it would take in salaries for qualified people to process applications.
- JumpCrisscross 12y ago> Why don't we spend $10M to bolster the review team and clear the queue instead of creating $150M worth of perverted incentives that the companies will inevitably recoup from the health care system? Because: 1. the $10 million would come out of the FDA's budget while the $150 million doesn't; and 2. spending $10 million to clear the queue would do nothing to incentivise drug development for neglected diseases, such as leishmaniasis.
- jonlucc 12y agoThese are both good points, but it is also important to note that it is not very easy to hire people to review drugs at the FDA. They have to be pretty aware of the state-of-the-art in their field in order to be able to effectively provide guidance to the drug companies.
- revelation 12y agoThe tremendous time and money requirement to navigate the FDA process for approval of a drug meanwhile does a lot to disincentivize the drug development for neglected diseases. It's biting its own tail.